Xing Dai

This inventor holds 40 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 21 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Merck Sharp + Dohme Corp., Inventisbio Co., Ltd., Inventisbio LLC. Active years: 2013-2026.

USPTO Granted Patents = 40 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 21 (Patent Applications = 14)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

Cranford, NJ (US) (2013 - 2021)
Short Hills, NJ (US) (2020 - 2024)
Shanghai, CN (2022 - 2024)

Company Filing History:

21 out of 2,405

Merck Sharp + Dohme Corp.

patents

12 out of 19

Inventisbio Co., Ltd.

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Selective Estrogen Receptor Degraders

BACE Inhibitors

Indoleamine-2,3-Dioxygenase Inhibitors

Leucine-Rich Repeat Kinase

Viral Disease Treatment

Hepatitis C Treatment

Tetracyclic Compounds

Substituted Benzofuran

Salt Forms

C5-C6-Oxacyclic Compounds

Spiro-Imidazolone Derivatives

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697337 - Solid dispersions (2026-08-04),

2. 12655123 - Heteroaryl compounds, solid forms, preparation methods and uses thereof (2026-06-16),

3. 12492184 - Heteroaryl compounds, preparation methods and uses thereof (2025-12-09),

4. 12187736 - Selective estrogen receptor degraders and uses thereof (2025-01-07),

5. 12173010 - Heterocyclic compounds, preparation methods therefor, and methods of uses thereof (2024-12-24),

6. 12110289 - Heterocyclic compounds, preparation methods and uses thereof (2024-10-08),

7. 11969425 - Inhibitor of indoleamine-2,3-dioxygenase (IDO) (2024-04-30),

8. 11903931 - Salts of selective estrogen receptor degraders (2024-02-20),

9. 11865115 - Heterocyclic compounds, preparation methods and uses thereof (2024-01-09),

10. 11691981 - Heterocyclic compounds, preparation methods therefor, and methods of uses thereof (2023-07-04),

11. 11685720 - Salt forms of URAT-1 inhibitors (2023-06-27),

12. 11639344 - EGFR inhibitors (2023-05-02),

13. 11339127 - Salt forms of URAT-1 inhibitors (2022-05-24),

14. 11241437 - Heterocyclic compounds, preparation methods and uses thereof (2022-02-08),

15. 11241418 - Salts of selective estrogen receptor degraders (2022-02-08),

Title: The Innovative Journey of Inventor Xing Dai

Introduction: Xing Dai, a talented inventor based in Cranford, NJ (US), has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Xing Dai holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: Throughout his career, Xing Dai has been recognized for his exceptional problem-solving skills and creativity, leading to the development of cutting-edge solutions that have positively impacted various industries.

Collaborations: Xing Dai has collaborated with leading research institutions, universities, and tech companies to further his inventions and bring them to market, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Xing Dai's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors, solidifying his legacy as a visionary in the world of technology.